Van Hulzen Asset Management LLC Has $30.19 Million Stake in Johnson & Johnson $JNJ

Key Points

• Van Hulzen Asset Management reduced its Johnson & Johnson stake by 4% in the second quarter, selling 4,943 shares. It still held 118,886 shares worth approximately $30.19 million, representing 2.1% of its portfolio.
• Johnson & Johnson reported quarterly EPS of $2.90, beating estimates by $0.06, while revenue rose 6.6% year over year to $25.31 billion. The company reaffirmed FY 2026 EPS guidance of $11.60–$11.75 and pays an annualized dividend of $5.36, yielding about 2%.
• The stock has a Moderate Buy consensus rating with an average analyst price target of $274.13, but investors should note recent insider selling and a failed Phase 2 depression-drug trial. Institutional investors own 69.55% of the company.

Van Hulzen Asset Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,886 shares of the company's stock after selling 4,943 shares during the quarter. Johnson & Johnson comprises 2.1% of Van Hulzen Asset Management LLC's portfolio, making the stock its 11th biggest position. Van Hulzen Asset Management LLC's holdings in Johnson & Johnson were worth $30,194,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Silver Coast Investments LLC raised its holdings in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after purchasing an additional 39 shares during the period. Townsend Asset Management Corp NC ADV boosted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management grew its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after buying an additional 39 shares during the period. Denali Advisors LLC increased its position in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after buying an additional 40 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC raised its stake in Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after buying an additional 42 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $267.35 on Thursday. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The company's fifty day simple moving average is $263.25 and its 200-day simple moving average is $246.40. The firm has a market cap of $644.28 billion, a PE ratio of 30.98, a P/E/G ratio of 2.55 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the previous year, the business earned $2.77 EPS. The company's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's payout ratio is currently 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising lung-cancer results strengthen J&J’s growth outlook. New Phase 2b and Phase 3 data showed that RYBREVANT-based combinations for EGFR-mutated non-small-cell lung cancer delivered improved tolerability, fewer treatment-related adverse events and longer reported overall survival. The results could support adoption of RYBREVANT and LAZCLUZE in first-line treatment. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Underlying business momentum remains resilient despite STELARA pressure. Management said sales increased 5.6% excluding the roughly 460-basis-point drag from STELARA, encouraging investors to focus on growth from the broader pharmaceutical and MedTech portfolios. The company previously reported quarterly revenue of $25.31 billion, up 6.6% year over year, and adjusted EPS above consensus. Should You Judge JNJ Stock Without STELARA?
• Positive Sentiment: Potential value creation from a DePuy Synthes sale is attracting investor interest. Apollo Global Management is reportedly considering acquiring J&J’s orthopedics business for close to $20 billion. A transaction could unlock value, sharpen J&J’s portfolio focus and provide capital for acquisitions or shareholder returns, although no deal has been announced. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Neutral Sentiment: J&J remains viewed as a defensive, dividend-oriented healthcare holding. Its roughly 2% yield, recent outperformance and FY 2026 EPS guidance of $11.60–$11.75 support the investment case, but a valuation near 31 times earnings leaves less room for execution disappointments.
• Negative Sentiment: A partnered depression drug failed a key Phase 2 endpoint. Contineum Therapeutics said the MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy goal in major depressive disorder. J&J is reviewing additional data, but the setback weakens the near-term pipeline contribution from the program. Johnson & Johnson-Partnered Contineum Depression Drug Fails Mid-Stage Trial
• Negative Sentiment: Reported insider activity shows executives have sold shares without any purchases during the past six months, a potentially cautionary sentiment signal, though such transactions may reflect diversification or scheduled sales rather than a fundamental view of JNJ.

Insider Buying and Selling

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 in the last three months. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on JNJ shares. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a report on Monday, August 3rd. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Guggenheim raised their price target on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. UBS Group began coverage on Johnson & Johnson in a report on Wednesday, September 2nd. They set a "buy" rating and a $320.00 price objective on the stock. Finally, Wells Fargo & Company boosted their price objective on Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.